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Abstract
Introduction: The prevalence of Helicobacter pylori infection (HPI) has been decreas-
ing in developed countries, with an increasing prevalence of Barrett’s esophagus (BE) 
and esophageal adenocarcinoma (EAC) at the same time. The aim of our meta- analysis 
was to quantify the risk of BE in the context of HPI.
Methods: A systematic search was conducted in 3 databases for studies on BE with 
data on prevalence of HPI from inception until December 2016. Odds ratios for BE in 
HPI were calculated by the random effects model with subgroup analyses for geo-
graphical location, presence of dysplasia in BE, and length of the BE segment.
Results: Seventy- two studies were included in the meta- analysis, including 84 717 
BE cases and 390 749 controls. The overall analysis showed that HPI reduces the risk 
of BE; OR = 0.68 (95% CI: 0.58- 0.79, P < .001). Subgroup analyses revealed risk re-
duction in Asia OR = 0.53 (95% CI: 0.33- 0.84, P = .007), Australia OR = 0.56 (95% CI: 
0.39- 0.80, P = .002), Europe OR = 0.77 (95% CI: 0.60- 0.98, P = .035), and North- 
America OR = 0.59 (95% CI: 0.47- 0.74, P < .001). The risk was significantly reduced 
for dysplastic BE, OR = 0.37 (95% CI: 0.26- 0.51, P < .001) for non- dysplastic BE, 
OR = 0.51 (95% CI: 0.35- 0.75, P = .001), and for long segment BE, OR = 0.25 (95% CI: 
0.11- 0.59, P = .001) in case of HPI.
Conclusions: This extensive meta- analysis provides additional evidence that HPI is 
associated with reduced risk of BE. Subgroup analyses confirmed that this risk reduc-
tion is independent of geographical location. HPI is associated with significantly 
lower risk of dysplastic, non- dysplastic, and long segment BE.
K E Y W O R D S
Barrett’s esophagus, esophageal adenocarcinoma, gastroesophageal reflux disease, 
Helicobacter pylori, meta-analysis, systematic review
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1  | BACKGROUND
Barrett’s esophagus (BE) is the only known precursor for esophageal 
adenocarcinoma (EAC).1 The prevalence of BE and incidence of EAC 
have been increasing in recent decades2 and EAC often is evolved in 
BE.1,3 At the same time, the prevalence of Helicobacter pylori infec-
tion (HPI) is decreasing in developed countries.4
There are multiple individual studies, both with evidence for and 
against the risk reduction in case of HPI. In 3 of the 4 previous meta- 
analyses, HPI proved to reduce the risk of BE.5-7 On the contrary, 
Wang et al8 did not find a clear relationship between HPI and BE in 
their analysis. The 3 earlier meta- analyses used small subsets of stud-
ies; they included 5, 9, and 12 trials.6-8 The most recent and exten-
sive meta- analysis of Fischbach identified 49 trials with data on the 
association between HPI and BE. Besides proving the risk reduction, 
their other main findings were the significant heterogeneity among 
the studies included and a marked risk reduction in the case of CagA- 
positive strains of H. pylori. The source of heterogeneity was one of 
the foci of their discussion and they concluded that both selection 
and information bias potentially contributed to their results.5
The above meta- analyses have not published analytical results 
of subgroup analysis for geographical location of the study popula-
tions, for the segment length of the BE, and for the presence of dys-
plasia in BE. Our aim was to update the most recent meta- analysis 
which included studies until 20105 and to investigate and quantify 
the risk of BE in these subgroups.
2  | METHODS
2.1 | Protocol
An epidemiological meta- analysis and systematic review was 
performed using the Preferred Reporting Items for Systematic 
Review	 and	 Meta-	Analysis	 Protocols	 (PRISMA-	P).9 The analysis 
was registered in advance on PROSPERO with registration number 
CRD42017077509.
2.2 | Search strategy
A	 systematic	 search	 was	 conducted	 in	 PubMed,	 EMBASE,	 and	
COCHRANE databases, from inception to December 2016. Records 
were managed by EndNote X7.4, software (Clarivate Analytics, 
Philadelphia, PA, USA) to exclude duplicates.
PICO items of the strategy were: (P) adult population with BE, (I) 
past or current HPI, (C) patients without BE, and (O) prevalence of 
HPI with and without BE.
Keywords for the computer- aided search were (Barrett’s OR 
Barrett’s metaplasia OR Barrett metaplasia OR Barrett’s oesophagus 
OR Barrett’s esophagus OR Barrett oesophagus OR Barrett esopha-
gus) AND (Helicobacter pylori or H pylori or H. pylori or Helicobacter). 
Additional articles were identified from the reference lists of eligible 
primary studies.
2.3 | Inclusion and exclusion criteria
All studies with relevant information on HPI prevalence in BE pa-
tients and controls within the same population were included in our 
analysis. All studies with abstracts in English were included; full- 
text articles in languages other than English were read, appraised, 
and data were extracted by researchers who spoke and under-
stood the respective language. Full- text articles and abstracts were 
both included. Different articles reporting data on the prevalence 
of HPI (proven by serological and/or histological studies and/or 
stool antigen testing and/or bacterial culture and/or rapid urease 
or urea breath test) and BE from the same population were thor-
oughly scrutinized and only one record with the highest number of 
BE cases was included in the meta- analysis. Articles from identical 
populations where the prevalence of HPI was more detailed for dif-
ferent lengths of BE were excluded from the overall analysis, but 
they were included in the subgroup analysis for BE segment length. 
All types of observational studies, such as case control and cross- 
sectional studies were included, regardless whether they were pro-
spective or retrospective. Non- human studies and review articles 
were excluded.
2.4 | Data extraction
Numeric data were extracted by 3 investigators and manually 
populated onto a purpose designed Excel 2016 sheet (Office 365, 
Microsoft,	Redmond,	WA,	USA).	Data	were	 collected	on	year	of	
publication, study type, geographical location, number of cases 
and controls, and basic demographics (age, sex ratio) in both 
groups	and	method(s)	of	HPI	testing.	Most	importantly,	data	were	
collected on the prevalence of HPI in BE cases and controls, also in 
dysplastic and non- dysplastic BE and in different segment lengths 
of BE, for further subgroup analysis. Data on prevalence of HPI 
by CagA- positive strains were also collected. Other relevant find-
ings were mentioned in an additional column as free text. The data 
extraction was reviewed and conflicts were resolved by the first 
author.
2.5 | Statistical analysis
Helicobacter pylori infection prevalence data from individual studies 
were extracted and raw data (number of BE patients with HPI, num-
ber of patients without HPI, number of controls with HPI, number of 
controls without HPI) were calculated, followed by the calculation 
of odds ratios (ORs) and 95% confidence intervals (CIs) for risk of 
BE in case of HPI. Adjusted ORs from the original articles were not 
extracted. Pooled estimates were calculated with random effects 
model using the DerSimonian- Laird method.10 Results of the meta- 
analysis were displayed graphically on forest plots. Heterogeneity 
was assessed using Cochrane’s Q and the I2 statistics, where Q ex-
ceeds the upper tail critical value of chi- square on k−1	degrees,	and	
I2 represents the percentage of effect size heterogeneity that can-
not be explained by random chance. As suggested by the Cochrane 
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Handbook, I2 values were interpreted as moderate (30%- 60%), sub-
stantial (50%- 90%), and considerable (75%- 100%) heterogeneity.11 
Publication biases of the included studies were checked by Egger’s 
test12 and by visual assessment of funnel plots.
All calculations were performed by Stata 11 data analysis and 
statistical software (Stata Corp LLC, College Station, TX, USA).
2.6 | Analysis of risk of bias and quality assessment
The assessments of both the risk of bias and the risk of quality were 
done at the outcome level.
A modified Newcastle- Ottawa Scale for case control studies was 
used for the quality assessment of the individual studies included in 
our meta- analysis, with the following items, and the result of the as-
sessment was graphically demonstrated in a table with color codes, 
green: low risk of bias; yellow: moderate or unknown risk of bias; red: 
high risk of bias.
The questions for the risk assessment were as follows:
1. Was the case definition clear? 
a. Yes, with positive endoscopic features of BE and supporting 
histology (green).
b. Yes, without history of BE (yellow).
c. No clear description of diagnosis of BE (red).
2. Were the BE cases representative? 
a. Yes, consecutive BE cases, without significant exclusion crite-
ria (green).
b. No, significant exclusion criteria or no description (red).
3. Was the selection of controls without selection bias? 
a. Yes, community controls (green).
b. Hospital controls (endoscopy, blood donors, etc.) (yellow).
c. No clear definition of controls (red).
4. Was the definition of controls clear? 
a. Yes, with an endoscopy excluding BE (green).
b. No or no endoscopic exclusion of BE (red).
5. Were the BE cases and controls comparable? 
a. Yes, with both age and sex matched (green).
b. Yes, with age or sex (yellow).
c. No (red).
6. Was the investigator blind to the presence of BE, when reading 
the result of H. Pylori test result, or vice versa? 
a. Yes, the study description clearly states it.
b. No or no clear description.
7. Was the same method used to test HPI in BE and controls? 
a. Yes (green).
b. No or no description (red).
3  | RESULTS
3.1 | Study selection
Our search strategy initially identified 1705 potential studies. 
Removal of duplicates was followed by screening first the titles, 
and then the abstracts, leaving 96 studies for full- text review, 
including 8 additional studies identified in the reference lists of 
the primary eligible studies.13-20 Thirteen studies were excluded, 
as they did not provide sufficient data (reasons for exclusion de-
tailed in Appendix S1). Data were extracted from 83 studies13-95; 
however, 11 of these studies had to be excluded from the statisti-
cal analysis as they contained data from same populations already 
described in other articles.22,35,38,39,52,56,65,68,80-82 Our final sta-
tistical analysis included 72 studies. Of the 72 articles, 2 studies 
contained data from populations already reported in the 70 stud-
ies; however, these had detailed data on the different prevalence 
of HPI in different segment lengths of BE, therefore these were 
only included in the subgroup analysis.45,84 The study selection 
process is shown in Figure 1. The summary of the characteristics 
of the studies included in our analysis is shown in Table 1.
3.2 | Results of statistical analysis
3.2.1 | Risk of Barrett’s esophagus in case of 
Helicobacter pylori infection
Our results confirmed an overall risk reduction OR = 0.68 (95% 
CI: 0.58- 0.79, P < .001) by the calculation from the data of the 70 
studies, including a total of more than 90 000 BE cases and nearly 
400 000 controls. Heterogeneity was substantial, I2 = 84.0%.
Subgroup analyses showed risk reduction in Asia, OR = 0.56 
(95% CI: 0.35- 0.90, P = .016), 14 studies; in Australia, OR = 0.56 
(95% CI: 0.39- 0.80, P = .002), 3 studies; in Europe, OR = 0.75 
(95% CI: 0.58- 0.96, P = .022), 31 studies, and in North- America, 
OR = 0.59 (95% CI: 0.47- 0.74, P < .001) 19 studies. The low number 
of studies with considerable selection and information bias from 
South- America14,33 and Africa25 means that the meta- analytical cal-
culations of the studies from these regions are not suitable for any 
conclusions, although these studies could not demonstrate a clear 
association between HPI and BE. Detailed results from the 70 stud-
ies are detailed in Figure 2.
3.2.2 | Risk of Barrett’s esophagus in case of CagA- 
positive Helicobacter pylori infection
There were 4 additional studies reporting the prevalence of 
CagA- positive HPI in relation to BE, in addition to the stud-
ies identified by Fischbach et al5 which included results from 7 
studies. In total, 11 studies were included in the subgroup analy-
sis.17,24,26,32,37,58,70,73,74,84,86 A further study from Abouda et al in 
2003 reported data on H. pylori strain positive for both CagA and 
VacA and not CagA strains only. As their data reported on a more 
specific H. pylori strain, their results were not included in our sub-
group analysis.13 The calculated risk reduction for BE in case of 
CagA- positive HPI is significant, OR = 0.50 (95% CI: 0.29- 0.87, 
P = .014). Fischbach et al calculated an OR = 0.38 (95% CI: 0.189- 
0.781), and our result confirms their finding. The forest plot of 
this subgroup analysis is shown in Figure S1.
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3.2.3 | Risk of different segment lengths of  
Barrett’s esophagus in case of Helicobacter 
pylori infection
Prevalence of HPI for different segment lengths of BE was 
detailed in 7 studies and data were suitable for meta- analy
sis.44,45,47,66,70,71,83,84,94 Two articles had detailed data on ultra-
short segment BE (USSBE, <1 cm)66,94 and they were not included 
in the short segment BE (SSBE) subgroup. We note that the new 
guideline of the British Society of Gastroenterology defines BE 
by at least 1 cm of metaplastic columnar lining, which questions 
the justification of the diagnosis of USSBE.96 However, the meta- 
analytical calculation was performed for this subgroup as well.
The risk reduction was statistically significant in the long seg-
ment BE (LSBE) subgroup OR = 0.25 (95% CI: 0.11- 0.59, P = .001). 
In SSBE, the pooled OR was not statistically significant, but there is 
likely a risk reduction, OR = 0.63 (95% CI: 0.32- 1.26, P = .191). The 
results on USSBE or intestinal metaplasia at the cardia are not suit-
able for any conclusion, but there does not seem to be a reduced 
risk. The results are detailed in Figure 3.
3.2.4 | Risk of dysplasia in Barrett’s esophagus in 
case of Helicobacter pylori infection
Prevalence of HPI in association with the presence of dysplasia in 
BE was detailed in 7 studies and data were suitable for meta- analy
F IGURE  1 Flow chart of the study selection process
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TABLE  1 Main	characteristics	of	the	studies	included
Study author and year Country
Number of cases/
controls
Helicobacter pylori 
testing method
Definition of 
controls Only new BE cases
Abbas (1995)21 Pakistan 29/29 H, R GERD No
Abe (2009)23 Japan 36/108 H, R, S Population Yes
Abouda (2003)13 UK 60/25 H, R, S Endoscopy No
Ackermack (2003)24 Netherlands 51/62 S Endoscopy Not stated
Ahmed (2004)25 Sudan 11/47 R GERD Not stated
Anderson (2008)26 Ireland 224/260 S Population Yes
Blaser (1991)27 USA 58/41 H,S Population Not stated
Carmona (2003)28 Mexico 24/232 R Endoscopy Not stated
Chacaltana (2009)14 Peru 11/911 H Other No
Chang (2010)29 China 32/41 H Endoscopy No
Chen (2016)30 Taiwan 161/644 R Endoscopy Not stated
Cooper (1991)31 UK 26/30 H GERD No
Corley (2008)32 USA 318/299 S Population Yes
Csendes (1997)33 Chile 100/190 H Endoscopy No
Dore (2016)34 Italy 131/1772 H, R, U Endoscopy No
El Serag (1999)15 USA 36/72 H GERD No
Fassan (2009)36 Italy 210/210 H Endoscopy Not stated
Ferrandez (2006)37 Spain 104/213 H, R, S, PCR Population No
Goldblum (2002)40 USA 70/60 H, S Endoscopy No
Hackelsberger (1998)41 Germany 16/315 H, R Endoscopy No
Henihan (1998)42 Ireland 82/40 H esophagus GERD No
Hilal (2016)43 USA 323/1849 H Endoscopy No
Hirota (1999)44 USA 104/738 H esophagus Endoscopy No
Inomata (2006)a45 Japan 36/80 H, R, S Endoscopy Not stated
Johansson (2007)46 Sweden 21/498 H esophagus Endoscopy No
Jonaitis (2011)47 Lithuania 33/160 H, R GERD Not stated
Kala (2007)16 Czech Rep. 22/173 H, R GERD No
Katsienlos (2013)48 Greece 75/1915 H, R Endoscopy Not stated
Keyashian (2013)49 USA 52/391 H, SA Endoscopy No
Kiltz (1999)50 Germany 35/320 R, S Endoscopy No
Kim (2006)51 S. Korea 31/224 H, R Endoscopy Not stated
Laheij (2002)53 Netherlands 23/528 H, R, C Endoscopy Not stated
Lam (2008)54 USA 56/280 S Endoscopy Yes
Lee (2011)55 Malaysia 15/104 H, R Endoscopy Not stated
Loffeld (1992)57 Netherlands 71/200 H esophagus, S Population Not stated
Loffeld (2000)58 Netherlands 36/454 H Endoscopy Yes
Loffeld (2004)59 Netherlands 307/5341 H, C Endoscopy No
Lord (2000)60 Australia 91/214 H Endoscopy No
Martinek	(2003)61 Czech Rep. 31/259 H, R Endoscopy Not stated
Meng	(2008)17 USA 28/104 PCR Endoscopy Not stated
Monkemuller	(2008)62 Germany 97/97 H Endoscopy No
Nandurkar (1997)63 Australia 46/112 H esophagus Endoscopy Yes
Newton (1997)64 UK 16/25 H, R Endoscopy No
Pascareno (2014)66 Romania 24/218 H Endoscopy Not stated
Paull (1988)67 USA 26/26 H Endoscopy No
(Continues)
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sis.36,42,78,79,86,87,90 We defined the subgroup of dysplastic BE by the 
presence of low- or high- grade dysplasia or adenocarcinoma in the BE.
The risk reduction was significant for dysplastic BE in case of 
HPI, OR = 0.37 (95% CI: 0.26- 0.51, P < .001). We note that the study 
by Henihan et al42 did not report any dysplastic BE with HPI; there-
fore, the result of their study could not be interpreted by the random 
effect model in this subgroup and had to be excluded.
In non- dysplastic BE, the risk reduction was also significant, 
OR = 0.51 (95% CI: 0.35- 0.75, P = .001). The results are detailed in 
Figure 4.
3.2.5 | Additional subgroup analyses to identify the 
source of heterogeneity
In order to understand the association between the risk of BE and 
the prevalence of HPI, further subgroup analyses were performed.
Stratification by the different control groups was possible for 4 
subgroups of studies with population, gastro- esophageal reflux dis-
ease (GERD), endoscopy, and other controls as indicated in Table 1. 
In subgroups of studies with population and GERD controls, the ORs 
were not significant. Only the studies with endoscopy controls showed 
a significant risk reduction OR = 0.48 (95% CI: 0.31- 0.74, P = .001). 
There was substantial and considerable heterogeneity among studies 
in all subgroups. The detailed results are shown in Figure S2.
Stratification by the H. pylori testing method was possible for 
4 subgroups of studies with histology from the stomach, histology 
from the esophagus, serology, and rapid urease test as indicated in 
Table 1. One study used polymerase chain reaction and in 30 stud-
ies multiple modalities were used for the detection of HPI. In case 
of rapid urease test and histology from the esophagus, the ORs 
from the studies cover a wide range and the pooled ORs for these 
methods are not significant. Significant risk reduction was seen in 
Study author and year Country
Number of cases/
controls
Helicobacter pylori 
testing method
Definition of 
controls Only new BE cases
Peng (2009)69 China 27/110 R GERD Not stated
Rajendra (2004)18 Malaysia 123/1741 H, R Endoscopy Not stated
Rajendra (2007)70 Malaysia 55/53 H, S Endoscopy No
Rex (2003)71 USA 48/764 R Population Yes
Rodriguez (2014)72 Spain 8/192 H Endoscopy Yes
Ronkainen (2005)19 Sweden 16/984 H, C, S Population Not stated
Rubenstein (2014)73 USA 150/177 S Endoscopy No
Rugge (2001)74 Italy 53/53 H Endoscopy Not stated
Sharifi (2014)76 Iran 34/702 H, R GERD Not stated
Schenk (1999)75 Netherlands 49/88 H GERD No
Sonnenberg (2010)77 USA 2510/76 475 H Endoscopy No
Sonnenberg (2016)78 USA 76 475/284 552 H Endoscopy No
Thrift (2012)79 Australia 0/398 S Population Yes
Toruner (2004)20 Turkey 29/306 H Endoscopy Yes
Uno (2011)83 Japan 126/100 H, S, R Endoscopy No
Vaezi (2000)a84 USA 83/60 H, S GERD Not stated
Veldhuyzen (2006)85 Canada 25/1015 H Endoscopy Yes
Vicari (1998)86 USA 48/57 H,S GERD No
Vieth (2000)87 Germany 1054/712 H Endoscopy No
Watari (2009)88 Japan 88/52 H, C Other No
Werdmuller (1997)89 Netherlands 13/399 H, C, R, S Endoscopy Not stated
Weston (2000)90 USA 208/217 H GERD No
White (2008)91 Canada 39/29 H esophagus Endoscopy No
Wong (2002)92 China 10/448 H, R, U Endoscopy Yes
Wu (2000)93 Hong Kong 6/85 H, R GERD Not stated
Zaninotto (2002)94 Italy 34/32 H esophagus GERD No
Zullo (2014)95 Italy 17/1037 H Endoscopy Not stated
C, culture; GERD, gastro- esophageal reflux disease; H, histology; PCR, polymerase chain reaction; R, rapid urease test; S, serology; SA, stool antigen; 
U, urea breath test.
aStudies only in the subgroup analysis for BE segment length.
These studies are indicated as H esophagus in column 4 (H. pylori testing method).
TABLE  1  (Continued)
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the pooled ORs for H. pylori testing by histology from the stomach 
and serology. Heterogeneities in all subgroups are substantial, save 
for serology where the studies showed no significant heterogeneity 
(I2 = 0%, P = .906). The detailed results are shown in Figure S3.
We identified 12 studies, which clearly stated that only new 
Barrett’s cases were included or previously diagnosed BE cases 
were excluded.20,23,26,32,54,58,63,71,72,79,85,92 The subgroup analysis 
showed an OR = 0.48 (95% CI: 0.34- 0.68, P < .001) with substantial 
heterogeneity (I2 = 60.6%, P = .003). The detailed results are shown 
in Figure S4.
3.2.6 | Risk of publication bias
The Egger’s tests calculated significant publication bias in the meta- 
analysis of all 70 studies, P < .001, but not in the subgroup analyses 
on the CagA status (P = .188), the segment length of BE (P = .051), the 
presence of dysplasia (P = .16), and the newly diagnosed BEs (P = .465).
A visual inspection of the funnel plot of the overall assessment 
from the 70 studies revealed asymmetry, Figure S5. There was no 
asymmetry on the funnel plots of the subgroup analyses.
3.2.7 | Risk of selection and information bias
The results of our quality and risk assessment by the modified 
Newcastle- Ottawa scale for case control studies are shown in 
Table 2.
It is important to note that our meta- analysis includes 78 studies 
of the meta- analysis by Fischer and our quality and risk assessment 
revealed both selection and information bias, which had been re-
ported by Fischbach et al5 In- depth scrutiny for causes of the bias 
in the additional 25 studies showed a similar pattern of flaws in the 
study design.
1. Lack of clear definition of BE. Although most of the studies 
defined it by endoscopy and histology findings at the same 
time, these diagnostic criteria show variability in time and place.
2. The BE cases included in the studies were often limited by many 
exclusion criteria.
3. We found only one study in which the controls truly represented 
the population79; most of the other studies used endoscopy con-
trols. A smaller proportion of studies used blood donors as controls, 
who are often healthier and younger than the normal population.
4. Selection of controls in endoscopy is necessary in the exclusion 
of asymptomatic Barrett’s patients from the controls, but it 
means that these controls go through a gastroscopy with the pur-
pose of investigating gastrointestinal symptoms, which most 
likely influences their prevalence of HPI even if there is no gastri-
tis or ulcer disease. Patients with gastro-esophageal reflux dis-
ease (GERD) formed the control group in several studies. This 
also results in bias, as there is convincing evidence that HPI re-
duces the risk of GERD.6
5. Comparability was poor in most of the studies, as only 23 of the 
studies had age- and sex-matched cases and controls and an 
additional 7 of them had either sex- or age-matched cases and con-
trols. Some of the studies described significantly different propor-
tion of races in the cases and controls and there is ample evidence 
that ethnicity influences the prevalence of both HPI and BE.49,54,65
6. Only 3 studies stated clearly that the investigators were 
blinded to BE when testing HPI or vice versa. In some of the 
articles, the study design suggested that the single pathologist 
involved was obviously aware of the BE and the HPI status 
when assessing the histology slides for BE and HPI, while in 
other studies the endoscopist was aware of the BE diagnosis at 
the time when the rapid urease test was performed. However, 
the vast majority of the studies did not describe the process of 
HPI ascertainment; this is also a potential source of bias.
7. Testing of HPI in the studies was performed by the same method 
in both groups in nearly all studies. However, some articles de-
scribed alternative methods of HPI testing (ie positive result of 
rapid urease test and/or histology and/or culture and/or serology 
and/or stool antigen test) and it is not clear what proportion of 
these tests were used in the cases and controls.
4  | DISCUSSION
4.1 | Strengths of the analysis
To date, this is the largest and most comprehensive meta- analysis 
in this topic and includes data from 5 continents and 72 individual 
studies. To our best knowledge, this is the first meta- analysis on the 
effect of HPI on the length of BE and the presence of dysplasia in BE.
4.2 | Limitations of the analysis
Due to the limitations of the studies, the inconsistency of results, 
the indirect nature of the evidence, and the imprecision and report-
ing bias, the grade of evidence is low at best, based on the Grading 
of Recommendations Assessment, Development and Evaluation 
(GRADE) tool. Therefore, further research on this topic would very 
likely have an impact.97
4.3 | Heterogeneity among the studies
Our subgroup analyses for geography, CagA status, segment length 
of BE, dysplastic BE, control groups, H. pylori testing method, and 
new diagnoses of BE revealed substantial and in cases considerable 
heterogeneity among the studies, apart from 3 subgroups in all ana-
lytical calculations.
There was no heterogeneity among studies from Australia, South 
America, and from studies where serology was used to detect HPI. 
In the subgroup of Australia and South America, the small subsets 
of studies, 3 and 2 respectively, caution us to conclude that geogra-
phy accounts for heterogeneity. However, subgroup analyses with 
smaller or more accurately specified geographic areas could show 
different results.
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F IGURE  2 Forest plot of the random effect analysis of the 70 studies included in the overall analysis, in subgroups for continents. OR, 
odds ratio; CI, 95% confidence interval; HP, Helicobacter pylori, weights of studies and heterogeneities are indicated too
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There were 6 studies in the subgroup with serology as the 
method of detection of HPI.24,26,32,54,73,79 The studies are from 2003 
to 2014, 3 studies from the USA, 1 from Netherlands, Ireland, and 
Australia, 3 studies with population, and 3 studies with endoscopy 
controls. Four of the studies used IgG enzyme assays, 1 western 
blot, and 1 did not specify the exact method. None of the testing 
enzyme assays were the same. However, the homogeneity among 
these studies suggests that risk stratification of BE by HPI status 
could be best assessed by a serological test.
4.4 | Potential explanations of our findings
The role of H. pylori in the pathogenesis of BE is often described 
as controversial.98 As mentioned before, our meta- analysis showed 
an inverse association between HPI and BE; however there are 
several previous studies with altogether different conclusions: re-
porting that HPI has no correlation with BE33,69 or even a positive 
association42,57	(describing	HPI	as	a	risk	factor).	Most	papers	(espe-
cially the ones with higher patient numbers) are in parallel with our 
findings.32,36,77
If we accept that HPI leads to risk reduction, the following 
question arises: What could be the cause or mechanism behind 
this inverse association? This question is not only important from 
a theoretical, but also from a clinical standpoint: understanding the 
mechanism is crucial for evaluating the risks and benefits of H. pylori 
eradication therapy, in addition to bringing us closer to explaining 
the increasing incidence of BE.
Helicobacter pylori infection is a proven risk factor for gastric 
non- cardia adenocarcinoma and other cancers including lymphoma; 
however not much is known about its relationship with gastric cardia 
and EAC.99 Epidemiological data show a simultaneous decline of HPI 
and increase in the aforementioned 2 tumor types. Along with the 
decrease of H. pylori positivity, the incidence of non- cardia adeno-
carcinomas is also falling.100
F IGURE  3 Forest plot of the random effect analysis of the 7 studies included in the subgroup analysis for different segment lengths of 
Barrett’s esophagus. LS, long segment; SS, short segment; USS, ultrashort- segment Barrett’s esophagus; OR, odds ratio, CI, 95% confidence 
interval; HP, Helicobacter pylori, weights of studies and heterogeneities are indicated too
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As to why and how exactly could HPI reduce the risk of BE de-
velopment, several theories exist, but none of them are considered 
proven.	Multiple	articles	attribute	this	fact	to	the	effect	of	H. pylori on 
the gastric mucosa: the microorganism causes a corpus- predominant 
gastritis, which leads to decreased gastric output. In this case, the 
esophagus is less exposed to the harmful effect of gastric acid, thus 
it has a reduced risk for developing BE and EAC.5,7,98,101
Several studies that did not find a negative correlation between 
HPI and BE only did so when looking at patients that were infected 
with a CagA- positive subgroup of H. pylori.99 Other articles that 
found an inverse association between H. pylori and BE reported an 
even stronger correlation when comparing only the CagA- positive 
subgroup instead of all H. pylori-positive patients.5,7,84
Chow et al and Vaezi et al hypothesize that this phenomenon 
might be caused by the CagA- positive sting’s increased virulence 
toward gastric mucosa and results in a multifocal atrophic gastri-
tis that also involves the destruction of gastric parietal cells, which 
further impairs acid secretion (more severely as compared to the 
CagA- negative subgroup). Consequently, the reduced acidity of the 
reflux’s convent reduces the risk of complications of GERD, such as 
BE and EAC.84,99
Contrary to this theory, based on a population- based Swedish 
case control study, Ye et al speculates that it is unlikely that H. pylori 
lowers the risk of BE through the reduction of gastric acidity. They 
drew this conclusion because no correlation was found between gas-
tric atrophy and EAC in their study; however, they did find a significant 
association between gastric atrophy and cardia adenocarcinoma.102
In a meta- analysis on the subject, Fischbach et al describes an-
other theory that aims to explain the inverse relationship between 
H. pylori and BE. They speculate that HPI is associated with reduced 
risk for obesity, thus not only reducing the likeliness for acidic reflux, 
but also the insulin level in the blood. This leads to the decreased 
production of Insulin- like Growth Factor (IGF), which normally acts 
as an agent that potentiates the proliferation of Barrett’s epithe-
lium.5 With the reduced amount of circulating IGF due to H. pylori, 
BE is less likely to develop.103
In contrast to these theories, Kountouras et al highlighted the 
conflicting nature of data available on this topic via editorial letters 
written in response to some previously cited articles. He mentions 
that	in	the	Malay	population,	H. pylori incidence is traditionally low; 
however, contrary to expectations, the incidence of BE and distal 
esophageal tumors is also below average.104
F IGURE  4 Forest plot of the random effect analysis of the 6 studies included in the subgroup analysis for the presence of dysplasia 
in Barrett’s esophagus. OR, odds ratio; CI, 95% confidence interval; HP, Helicobacter pylori, weights of studies and heterogeneities are 
highlighted too
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He not only points to the fact that according to several studies H. py-
lori might be a risk factor for BE, but also describes potential mechanisms 
to explain this positive connection. He states that H. pylori- induced over-
production of gastrin contributes to neoplastic progression in Barrett’s 
through pathway signaling. Furthermore, H. pylori also has a pro- 
inflammatory effect that might also potentiate the said progression.105
According to our results and the majority of conclusions avail-
able in the literature, a persistent HPI would be desirable for the 
prevention of BE. However, it is exactly the aforementioned atro-
phic gastritis that acts as the main risk factor for gastric non- cardia 
adenocarcinoma. This 2- sided effect of H. pylori is what causes clini-
cians to pose the question that is penitently described as Hamletic 
by Zullo et al101: to eradicate or not to eradicate? However, we have 
to emphasize that there is no evidence that should prevent us from 
eradicating H. pylori, regardless of coexisting reflux esophagitis or 
BE. HPI needs treatment, when it is identified.
An editorial in Gastroenterology elaborates on the possibil-
ity that the decline in H. pylori incidence might have other conse-
quences, not necessarily limited to the field of gastroenterology. 
For example, H. pylori might have an effect in regulating ghrelin and 
leptin, 2 hormones produced (partly in case of leptin) by the stomach 
and related to metabolism regulation. The article suggests that with 
the continuous fall of H. pylori incidence, we might see an increase in 
diabetes and obesity due to the dysregulation of these hormones.100
Our results confirm the conclusion of previous meta- analyses5-7 
and we calculated a similar magnitude of risk reduction. Gisbert 
et al6 in 2002 calculated an OR = 0.60 (95% CI: 0.48- 0.76), Rokkas 
et al7 in 2007 found an OR = 0.64 (95% CI: 0.43- 0.94, P = .025), and 
Fischbach et al5 in 2012 reported a RR = 0.73 (95% CI: 0.66- 0.80).
In summary, HPI is associated with a reduced risk of BE. Our new 
findings prove that the risk reduction in case of HPI seems to be inde-
pendent of the geographical location and it is directly associated with 
the length of the BE segment and the presence of dysplasia in BE.
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TABLE  2 Results of the modified Newcastle- Ottawa quality assessment scale for case control studies
Items in columns 1: Clear definition of BE cases, 2: Representativeness of BE cases, 3: Selection of controls, 4: Clear definition of controls, 5: Comparable 
BE cases and controls, 6: Investigator blinded for the ascertainment of the HPI 7: Same method of testing of HPI in BE cases and controls. Green: low 
risk of bias, yellow: moderate or unknown risk of bias, red: high risk of bias.
aStudies included only in the subgroup analysis for the different segment lengths of BE.
bHelicobacter pylori tested in esophageal or gastro- esophageal junction samples only.
Study author and year 1 2 3 4 5 6 7
Abbas (1995)21 ● ● ● ● ● ● ●
Abe (2009)23 ● ● ● ● ● ● ●
Abouda (2003)13 ● ● ● ● ● ● ●
Ackermack (2003)23 ● ● ● ● ● ● ●
Ahmed (2004)25 ● ● ● ● ● ● ●
Anderson (2008)26 ● ● ● ● ● ● ●
Blaser (1991)27 ● ● ● ● ● ● ●
Carmona (2003)28 ● ● ● ● ● ● ●
Chacaltana (2009)14 ● ● ● ● ● ● ●
Chang (2010)29 ● ● ● ● ● ● ●
Chen (2016)30 ● ● ● ● ● ● ●
Cooper (1991)31 ● ● ● ● ● ● ●
Corley (2008)32 ● ● ● ● ● ● ●
Csendes (1997)33 ● ● ● ● ● ● ●
Dore (2016)34 ● ● ● ● ● ● ●
El Serag (1999)15 ● ● ● ● ● ● ●
Fassan (2009)36 ● ● ● ● ● ● ●
Ferrandez (2006)37 ● ● ● ● ● ● ●
Goldblum (2002)40 ● ● ● ● ● ● ●
Hackelsberger (1998)41 ● ● ● ● ● ● ●
Henihan (1998)b 42 ● ● ● ● ● ● ●
Hilal (2016)43 ● ● ● ● ● ● ●
Hirota (1999)b 44 ● ● ● ● ● ● ●
Inomata (2006)a 45 ● ● ● ● ● ● ●
Johansson (2007)b 46 ● ● ● ● ● ● ●
Jonaitis (2011)47 ● ● ● ● ● ● ●
Kala (2007)16 ● ● ● ● ● ● ●
Katsinelos (2013)48 ● ● ● ● ● ● ●
Keyashian (2013)49 ● ● ● ● ● ● ●
Kiltz (1999)50 ● ● ● ● ● ● ●
Kim (2006)51 ● ● ● ● ● ● ●
Laheij (2002)53 ● ● ● ● ● ● ●
Lam  (2008)54 ● ● ● ● ● ● ●
Lee (2011)55 ● ● ● ● ● ● ●
Loffeld (1992)b 57 ● ● ● ● ● ● ●
Loffeld (2000)58 ● ● ● ● ● ● ●
Loffeld (2004)59 ● ● ● ● ● ● ●
Lord (2000)60 ● ● ● ● ● ● ●
Martinek (2003)61 ● ● ● ● ● ● ●
Meng (2008)17 ● ● ● ● ● ● ●
Monkemuller (2008)62 ● ● ● ● ● ● ●
Nandurkar (1997)b 63 ● ● ● ● ● ● ●
Newton (1997)64 ● ● ● ● ● ● ●
Pascareno (2014)66 ● ● ● ● ● ● ●
Paull (1988)67 ● ● ● ● ● ● ●
Peng (2009)69 ● ● ● ● ● ● ●
Rajendra (2004)18 ● ● ● ● ● ● ●
Rajendra (2007)70 ● ● ● ● ● ● ●
Rex (2003)71 ● ● ● ● ● ● ●
Rodriguez (2014)72 ● ● ● ● ● ● ●
Ronkainen (2005)19 ● ● ● ● ● ● ●
Rubenstein (2014)73 ● ● ● ● ● ● ●
Rugge (2001)74 ● ● ● ● ● ● ●
Sharifi (2014)76 ● ● ● ● ● ● ●
Schenk (1999)76 ● ● ● ● ● ● ●
Sonnenberg (2010)77 ● ● ● ● ● ● ●
Sonnenberg (2016)78 ● ● ● ● ● ● ●
Thrift (2012)79 ● ● ● ● ● ● ●
Toruner (2004)20 ● ● ● ● ● ● ●
Uno (2011)83 ● ● ● ● ● ● ●
Vaezi (2000)a 84 ● ● ● ● ● ● ●
Veldhuyzen (2006)85 ● ● ● ● ● ● ●
Vicari (1998)86 ● ● ● ● ● ● ●
Vieth (2000)87 ● ● ● ● ● ● ●
Watari (2009)88 ● ● ● ● ● ● ●
Werdmuller (1997)89 ● ● ● ● ● ● ●
Weston (2000)90 ● ● ● ● ● ● ●
White (2008)b 91 ● ● ● ● ● ● ●
Wong (2002)92 ● ● ● ● ● ● ●
Wu (2000)93 ● ● ● ● ● ● ●
Zaninotto (2002)b 94 ● ● ● ● ● ● ●
Zullo (2014)95 ● ● ● ● ● ● ●
Study author and year 1 2 3 4 5 6 7
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